A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients - PACIFIC-5

Exclusion Criteria

• 1. History of allogeneic organ transplantation, or another primary malignancy, or active primary immunodeficiency.
• 2. Active or prior documented autoimmune or inflammatory disorders
• 3. Uncontrolled intercurrent illness that would limit compliance with study requirement, substantially increase risk of incurring AEs, or compromise the ability of the patient to give written informed consent
• 4. Active infection including tuberculosis hepatitis B hepatitis C (HCV), or human immunodeficiency virus (positive human immunodeficiency virus [HIV] 1/2 antibodies).
• 5. Mixed small cell and NSCLC histology, sarcomatoid variant
• 6. Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 from the prior chemoradiation therapy.
• 7. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.
• 8. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.